This unique platform provides early analysis of drug candidates from small molecules to 
biologics, before the classical preclinical stage. By eliminating low-value molecules early, 
INOVOTION accelerates the drug discovery process, increases the R&D productivity, and 
reduces its costs.  

INOVOTION built this xenograft model using chicken embryo because it has tremendous 
benefits: fast, robust, affordable, and predictive. These in vivo assays will save time and give 
a clear competitive advantage to public and private researchers.  

This next generation of in vivo efficacy and toxicity tests covers fours main aspects:  
- Efficacy assays for anti-cancer treatments including antibodies and immune-checkpoints  
- Early Toxicity assays for drug candidates  
- Target Validation in oncology  
- Multi-Cancer Screening to (re)positioning a treatment  

INOVOTION has been invited by prof.dr. Ronit Shiri-Sverdlov as part of the monthly Scientific Meeting with Division II within NUTRIM.